New targets for Parkinson's revealed in gene network

Using RNA interference technology, scientists have discovered a network of genes that could serve as new therapeutic targets for Parkinson's disease as well as other diseases characterized by mitochondrial damage.  

Biota halts preclinical antibiotics program as antimicrobial resistance grows

Amidst a challenging R&D environment, Atlanta-based Biota Pharmaceuticals has dumped its preclinical antibiotics program, saying that it will continue to seek out licensing agreements and other deals to advance the development of its candidates.

Eli Lilly, Project A.L.S. forge preclinical drug discovery pact

Eli Lilly and the nonprofit Project A.L.S. are teaming up to boost the pipeline of potential drugs for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig' disease.

Inovio DNA vaccine protects against MERS in mice

A DNA vaccine developed by Blue Bell, PA-based Inovio Pharmaceuticals induced robust and durable immune responses against the deadly MERS coronavirus in a preclinical model. 

Compound that targets fat-burning mechanism discovered

Austrian researchers have discovered a compound that may be able to activate a protein in the body to trigger fat burning.

Herb-based compounds improve learning, memory in Alzheimer's mice

The antidote for Alzheimer's may be hidden in two common herbs. A study conducted at Saint Louis University found that enhanced extracts derived from antioxidants in spearmint and rosemary improved learning and memory in mice.

Bacteria-derived toxin could provide design for new antibiotics

Investigators at MIT may have found the key to designing the next generation of antibiotics--a toxin called SocAB that blocks DNA replication and inhibits bacterial growth.

First-ever 'mini-kidney' organs created from human stem cells

Three-dimensional kidney structures created for the first time in a laboratory by scientists at the Salk Institute for Biological Studies could provide a new possibility for developing drugs that treat kidney disease and restore kidney function.

Oxford, MRC Technology team up on migraine drug discovery

Oxford University scientists are teaming up with London-based MRC Technology, a tech transfer nonprofit, to screen selective and potent potassium channel activators that could be formulated into new therapies for migraine relief. 

Tekmira's RNAi antivirals protect animals from lethal doses of Ebola, Marburg

Canada's Tekmira Pharmaceuticals ($TKMR) has unveiled new data showing that its antiviral RNA interference therapeutics were effective at abolishing Ebola and Marburg viruses in preclinical studies when treatment was delayed.

New drug target identified for glioblastoma

A cellular pathway interaction that plays a role in repairing serious injuries may also be a promising target for preventing the spread of a deadly type of brain cancer, according to a new study.

Compound mimicking gene deletion stops tissue scarring in mice

By targeting a family of proteins on the surface of certain cells, scientists have been able to halt and reverse tissue scarring in liver, kidneys and lungs in mice.

MacroGenics to receive $9M from Boehringer Ingelheim in preclinical antibody pact

Boehringer Ingelheim has chosen an antibody therapeutic candidate discovered by Rockville, MD-based MacroGenics for preclinical development. 

Government shutdown effects on biomedical research outlined

The White House's Office of Management and Budget released a new report that sheds light on how the 16-day federal government shutdown in October impacted scientific research.

Japanese fund awards $5.7M in infectious disease vaccine work

A new public health partnership called the Global Health Innovative Technology Fund is doling out $5.7 million in grants to 6 programs across the globe to boost research and development of promising vaccines against malaria, tuberculosis and Chagas disease.

Report proposes revamping Alzheimer's R&D

The number of failures in the Alzheimer's drug research field has been piling up disproportionately compared to successes in recent years, and the New York Academy of Sciences is hoping to change that by proposing a more streamlined, efficient path for Alzheimer's drug development.

Study: Genetics drive neurocognitive decline in aging

A person's genetics are responsible for a decline in brain function in normal aging, according to a new study conducted by researchers at the Texas Biomedical Research Institute in San Antonio and Yale University.

Sage molecule could treat a wide range of CNS disorders

Scientists at the Cambridge, MA, startup Sage Therapeutics have discovered an innate mechanism that indirectly influences a key receptor linked to a number of neurologic and psychiatric disorders, including Alzheimer's, schizophrenia, autism and depression.

Fewer NIH grants affected by sequestration than initially projected

NIH has issued an updated fact sheet on the impact of federal sequestration, which totaled nearly $1.6 billion in cuts this year.

Prana compound restores learning, memory loss in mice

Australian Prana Biotechnology has published new data showing its metal-transporting compound PBT2 reversed memory and learning loss associated with the aging process in elderly mice.